Daryl Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daryl Cheng has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Jacob
UCL Respiratory, University College London, London, UK
8 shared publications Arjun Nair
Department of Radiology, University College London Hospitals NHS Trust, London, UK
4 shared publications- Daisuke Yamada
UCL Hawkes Institute, Satsuma Lab, University College London, London, UK
4 shared publications Mehran Azimbagirad
Department of Computer Science, UCL Hawkes Institute, University College London, London, UK
4 shared publicationsShahab Aslani
Department of Computer Science, UCL Hawkes Institute, University College London, London, UK
4 shared publicationsShanshan Wang
Department of Computer Science, UCL Hawkes Institute, University College London, London, UK
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Scientific Reports
Imaging-based biological age estimation predicts competing mortality risk in lung cancer screening
Lung cancer screening (LCS) participants have a high competing risk of non-lung cancer related death, which limits screening benefit. We hypothesized that imaging-based biological age can identify individuals at higher risk of non-lung cancer mortality. Low dose computed tomography scans from a large LCS trial were retrospectively analyzed. Bone density loss, muscular fat infiltration, vascular calcification, and visceral fat mass were calculated using segmentations from a nnU-Net based deep learning segmentation model. Each participant’s age gap, defined as the difference between their estimated biological age and chronological age, was estimated with disease course mapping using a Bayesian mixed-effects model. Disease course map construction used all available longitudinal scan data, whilst individual biological age prediction used baseline scan data only. The performance of age gap as a parameter in competing risk models for non-lung cancer related death versus lung cancer diagnosis was evaluated, following the TRIPOD + AI reporting guideline. We included 29,745 scans from 12,478 participants in the final analysis. Median follow-up was 5 years, representing 58,284 person-years at risk. Multivariable survival models of competing risks were constructed, including the estimated age gap. The subdistribution hazard ratio (sHR) for each decade of age gap for non-lung cancer related death was higher (sHR = 2.0, 95% CI 1.8–2.3), compared to lung cancer diagnosis (sHR = 1.3, 95% CI 1.2–1.5). Addition of age gap improved model concordance of non-lung cancer death compared to a model with clinical variables alone (pooled C-index = 0.69 vs 0.73, difference + 0.04, 95% CI 0.03–0.04, p < 0.001). Biological age estimation using an imaging-based disease progression model improves prediction of non-lung cancer related death in lung cancer screening.
- 15 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessImaging-based biological age estimation predicts competing mortality risk in lung cancer screening
Lung cancer screening (LCS) participants have a high competing risk of non-lung cancer related death, which limits screening benefit. We hypothesized that imaging-based biological age can identify individuals at higher risk of non-lung cancer mortality. Low dose computed tomography scans from a large LCS trial were retrospectively analyzed. Bone density loss, muscular fat infiltration, vascular calcification, and visceral fat mass were calculated using segmentations from a nnU-Net based deep learning segmentation model. Each participant’s age gap, defined as the difference between their estimated biological age and chronological age, was estimated with disease course mapping using a Bayesian mixed-effects model. Disease course map construction used all available longitudinal scan data, whilst individual biological age prediction used baseline scan data only. The performance of age gap as a parameter in competing risk models for non-lung cancer related death versus lung cancer diagnosis was evaluated, following the TRIPOD + AI reporting guideline. We included 29,745 scans from 12,478 participants in the final analysis. Median follow-up was 5 years, representing 58,284 person-years at risk. Multivariable survival models of competing risks were constructed, including the estimated age gap. The subdistribution hazard ratio (sHR) for each decade of age gap for non-lung cancer related death was higher (sHR = 2.0, 95% CI 1.8–2.3), compared to lung cancer diagnosis (sHR = 1.3, 95% CI 1.2–1.5). Addition of age gap improved model concordance of non-lung cancer death compared to a model with clinical variables alone (pooled C-index = 0.69 vs 0.73, difference + 0.04, 95% CI 0.03–0.04, p < 0.001). Biological age estimation using an imaging-based disease progression model improves prediction of non-lung cancer related death in lung cancer screening.
- Open Access
- 7 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Pulmonary arterial volume and mortality in smokers without chronic obstructive pulmonary disease
- 7 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Open AccessPulmonary arterial volume and mortality in smokers without chronic obstructive pulmonary disease
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Quantitative CT Imaging Biomarkers To Predict Incident Cardiovascular Events In Smoking-Exposed Populations: A Systematic Review And External Validation
Background: Chest CT acquired in lung cancer screening (LCS) contains quantifiable information relevant to cardiovascular health that is rarely reported. Automated CT biomarkers have been proposed as cardiovascular predictors, but whether they add value to readily available clinical information is unknown.Methods: We searched MEDLINE, Embase and Web of Science to April 7, 2026, for automated or semi-automated non-gated chest CT biomarkers reported to predict incident cardiovascular events in smoking-exposed adults; findings were synthesised narratively. Biomarkers measurable with an equivalent automated pipeline were externally validated in SUMMIT, a UK LCS cohort, against MACE-5 (cardiovascular death, or admission for myocardial infarction, stroke, unstable angina or heart failure). Cause-specific Cox models were fitted univariably, adjusted for demographics and smoking (multivariable), and additionally for the radiologist’s visual coronary calcium score, blood pressure and diabetes (enhanced). Incremental value was quantified as the change in Harrell’s C-statistic against a reference model without the biomarker, and net benefit using decision curve analysis.Findings: Of 1630 records, 14 studies reporting nine biomarkers were eligible; ten analysed one of two screening trials and none was at low risk of bias. Six biomarkers were validated in 13 035 SUMMIT participants, among whom 977 MACE-5 events occurred over a median 6·28 years. In multivariable models, coronary artery calcium volume (hazard ratio per SD 2·03, 95% CI 1·85–2·22), thoracic aorta calcium volume (1·75, 1·59–1·93), airway wall thickness (1·21, 1·14–1·29) and epicardial adipose tissue volume (1·18, 1·09–1·28) were associated with MACE-5, but emphysema and epicardial adipose tissue density were not. Only coronary artery calcium volume (change in C-statistic 0·063, 0·047–0·078) and thoracic aorta calcium volume (0·040, 0·027–0·050) materially improved discrimination, and both increased net benefit across a wide range of thresholds in multivariable models. In enhanced models (including visual coronary calcium score), improvement in C-statistic was minimal for all biomarkers.Interpretation: Automated CT biomarkers were associated with cardiovascular events in an independent lung cancer screening cohort, but only coronary and thoracic aorta calcium improved discrimination and net benefit beyond demographic and smoking data, and neither added materially to the radiologist’s visual calcium score. Validation studies of imaging biomarkers should report incremental discrimination and net benefit against relevant comparators, as evidence of clinical utility.FundingWellcome Trust; National Institute for Health and Care Research; Chan Zuckerberg Initiative Foundation; GRAIL Inc.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessQuantitative CT Imaging Biomarkers To Predict Incident Cardiovascular Events In Smoking-Exposed Populations: A Systematic Review And External Validation
Background: Chest CT acquired in lung cancer screening (LCS) contains quantifiable information relevant to cardiovascular health that is rarely reported. Automated CT biomarkers have been proposed as cardiovascular predictors, but whether they add value to readily available clinical information is unknown.Methods: We searched MEDLINE, Embase and Web of Science to April 7, 2026, for automated or semi-automated non-gated chest CT biomarkers reported to predict incident cardiovascular events in smoking-exposed adults; findings were synthesised narratively. Biomarkers measurable with an equivalent automated pipeline were externally validated in SUMMIT, a UK LCS cohort, against MACE-5 (cardiovascular death, or admission for myocardial infarction, stroke, unstable angina or heart failure). Cause-specific Cox models were fitted univariably, adjusted for demographics and smoking (multivariable), and additionally for the radiologist’s visual coronary calcium score, blood pressure and diabetes (enhanced). Incremental value was quantified as the change in Harrell’s C-statistic against a reference model without the biomarker, and net benefit using decision curve analysis.Findings: Of 1630 records, 14 studies reporting nine biomarkers were eligible; ten analysed one of two screening trials and none was at low risk of bias. Six biomarkers were validated in 13 035 SUMMIT participants, among whom 977 MACE-5 events occurred over a median 6·28 years. In multivariable models, coronary artery calcium volume (hazard ratio per SD 2·03, 95% CI 1·85–2·22), thoracic aorta calcium volume (1·75, 1·59–1·93), airway wall thickness (1·21, 1·14–1·29) and epicardial adipose tissue volume (1·18, 1·09–1·28) were associated with MACE-5, but emphysema and epicardial adipose tissue density were not. Only coronary artery calcium volume (change in C-statistic 0·063, 0·047–0·078) and thoracic aorta calcium volume (0·040, 0·027–0·050) materially improved discrimination, and both increased net benefit across a wide range of thresholds in multivariable models. In enhanced models (including visual coronary calcium score), improvement in C-statistic was minimal for all biomarkers.Interpretation: Automated CT biomarkers were associated with cardiovascular events in an independent lung cancer screening cohort, but only coronary and thoracic aorta calcium improved discrimination and net benefit beyond demographic and smoking data, and neither added materially to the radiologist’s visual calcium score. Validation studies of imaging biomarkers should report incremental discrimination and net benefit against relevant comparators, as evidence of clinical utility.FundingWellcome Trust; National Institute for Health and Care Research; Chan Zuckerberg Initiative Foundation; GRAIL Inc.
- 30 April 2026
- Published by Elsevier in Clinical Radiology
- Vol. 98, 107375
A deep learning lung cancer segmentation pipeline to facilitate CT-based radiomics
- 30 April 2026
- Published by Elsevier in Clinical Radiology
- Vol. 98, 107375
A deep learning lung cancer segmentation pipeline to facilitate CT-based radiomics
- Open Access
- 4 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
A computationally frugal, open-source chest CT foundation model for thoracic disease detection in lung cancer screening programmes
Background: Low-dose computed tomography (LDCT) employed in lung cancer screening (LCS) programmes is increasing in uptake worldwide. LCS programmes herald a generational opportunity to simultaneously detect cancer and non-cancer-related early-stage lung disease, yet these efforts are hampered by a shortage of radiologists to interpret scans at scale. Here, we present TANGERINE, a computationally frugal, open-source vision foundation model for volumetric LDCT analysis. Methods: Designed for broad accessibility and rapid adaptation, TANGERINE can be fine-tuned off the shelf for a wide range of disease-specific tasks with limited computational resources and training data. The model is pretrained using self-supervised learning on more than 98,000 thoracic LDCT scans, including the United Kingdom’s largest LCS initiative to date and 27 public datasets. By extending a masked autoencoder framework to three-dimensional imaging, TANGERINE provides a scalable solution for LDCT analysis, combining architectural simplicity, public availability, and modest computational requirements. Results: TANGERINE demonstrates superior computational and data efficiency in a retrospective multi-dataset analysis: it converges rapidly during fine-tuning, requiring significantly fewer graphics processing unit hours than models trained from scratch, and achieves comparable or superior performance using only a fraction of the fine-tuning data. The model achieves strong performance across 14 disease classification tasks, including lung cancer and multiple respiratory diseases, and generalises robustly across diverse clinical centres. Conclusions: TANGERINE’s accessible, open-source, lightweight design lays the foundation for rapid integration into next-generation medical imaging tools, enabling lung cancer screening programmes to pivot from a singular focus on lung cancer detection toward comprehensive respiratory disease management in high-risk populations.
- 4 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessA computationally frugal, open-source chest CT foundation model for thoracic disease detection in lung cancer screening programmes
Background: Low-dose computed tomography (LDCT) employed in lung cancer screening (LCS) programmes is increasing in uptake worldwide. LCS programmes herald a generational opportunity to simultaneously detect cancer and non-cancer-related early-stage lung disease, yet these efforts are hampered by a shortage of radiologists to interpret scans at scale. Here, we present TANGERINE, a computationally frugal, open-source vision foundation model for volumetric LDCT analysis. Methods: Designed for broad accessibility and rapid adaptation, TANGERINE can be fine-tuned off the shelf for a wide range of disease-specific tasks with limited computational resources and training data. The model is pretrained using self-supervised learning on more than 98,000 thoracic LDCT scans, including the United Kingdom’s largest LCS initiative to date and 27 public datasets. By extending a masked autoencoder framework to three-dimensional imaging, TANGERINE provides a scalable solution for LDCT analysis, combining architectural simplicity, public availability, and modest computational requirements. Results: TANGERINE demonstrates superior computational and data efficiency in a retrospective multi-dataset analysis: it converges rapidly during fine-tuning, requiring significantly fewer graphics processing unit hours than models trained from scratch, and achieves comparable or superior performance using only a fraction of the fine-tuning data. The model achieves strong performance across 14 disease classification tasks, including lung cancer and multiple respiratory diseases, and generalises robustly across diverse clinical centres. Conclusions: TANGERINE’s accessible, open-source, lightweight design lays the foundation for rapid integration into next-generation medical imaging tools, enabling lung cancer screening programmes to pivot from a singular focus on lung cancer detection toward comprehensive respiratory disease management in high-risk populations.
- Open Access
- 10 April 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Associations of preserved ratio impaired spirometry with cardiometabolic comorbidities: a systematic review and meta-analysis
Background: Preserved ratio impaired spirometry (PRISm) is a prevalent lung function abnormality associated with an increased body mass index and an increased risk of cardiovascular disease and metabolic disorders. However, the strength and consistency of these associations across populations remain unclear. This systematic review and meta-analysis aimed to quantify the relationship between PRISm and key cardiometabolic comorbidities, including diabetes mellitus, hypertension, hypercholesterolaemia, ischaemic heart disease and heart failure. Methods: A systematic search of PubMed, Embase and Web of Science was conducted to identify observational studies comparing the prevalence of cardiometabolic comorbidities in PRISm and normal spirometry populations. Meta-analyses were performed for conditions reported in three or more studies, and heterogeneity was assessed using the I 2 statistic. Sensitivity and influence analyses were conducted to ensure the robustness of findings. Results: A total of 18 studies were included, comprising over 500 000 participants. Meta-analysis showed significant associations between PRISm and diabetes (OR 2.08, 95% CI 1.78–2.42), hypertension (OR 1.78, 95% CI 1.55–2.03), ischaemic heart disease (OR 2.05, 95% CI 1.59–2.64), heart failure (OR 2.82, 95% CI 1.40–5.67) and hypercholesterolaemia (OR 1.46, 95% CI 1.16–1.85). PRISm populations also exhibited a higher body mass index (mean difference 1.49 kg·m −2 , 95% CI 0.92–2.05 kg·m −2 ). Conclusion: PRISm is strongly associated with cardiometabolic disease, reinforcing its role as a systemic condition rather than a purely pulmonary abnormality. These findings highlight the need for integrated screening and management strategies for PRISm patients to address their broader multimorbid risk profile.
- 10 April 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessAssociations of preserved ratio impaired spirometry with cardiometabolic comorbidities: a systematic review and meta-analysis
Background: Preserved ratio impaired spirometry (PRISm) is a prevalent lung function abnormality associated with an increased body mass index and an increased risk of cardiovascular disease and metabolic disorders. However, the strength and consistency of these associations across populations remain unclear. This systematic review and meta-analysis aimed to quantify the relationship between PRISm and key cardiometabolic comorbidities, including diabetes mellitus, hypertension, hypercholesterolaemia, ischaemic heart disease and heart failure. Methods: A systematic search of PubMed, Embase and Web of Science was conducted to identify observational studies comparing the prevalence of cardiometabolic comorbidities in PRISm and normal spirometry populations. Meta-analyses were performed for conditions reported in three or more studies, and heterogeneity was assessed using the I 2 statistic. Sensitivity and influence analyses were conducted to ensure the robustness of findings. Results: A total of 18 studies were included, comprising over 500 000 participants. Meta-analysis showed significant associations between PRISm and diabetes (OR 2.08, 95% CI 1.78–2.42), hypertension (OR 1.78, 95% CI 1.55–2.03), ischaemic heart disease (OR 2.05, 95% CI 1.59–2.64), heart failure (OR 2.82, 95% CI 1.40–5.67) and hypercholesterolaemia (OR 1.46, 95% CI 1.16–1.85). PRISm populations also exhibited a higher body mass index (mean difference 1.49 kg·m −2 , 95% CI 0.92–2.05 kg·m −2 ). Conclusion: PRISm is strongly associated with cardiometabolic disease, reinforcing its role as a systemic condition rather than a purely pulmonary abnormality. These findings highlight the need for integrated screening and management strategies for PRISm patients to address their broader multimorbid risk profile.
- Open Access
- 27 March 2025
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 10, 164
Prevalent comorbidity in patients with hypersensitivity pneumonitis: a UK primary care population study
Background Existing data on the prevalence of comorbidities in patients prior to a diagnosis of hypersensitivity pneumonitis (HP) is sparse. Methods Patients with two read codes of HP diagnosed between 01/01/1997 and 01/01/2019, were identified from the Clinical Practice Research Datalink GOLD database multiple registrations cohort. Included patients with a restrictive defect on pulmonary function testing were defined as probable fibrotic HP (pfHP). The incidence of a range of comorbidities was compared to age, gender and smoking matched patients with chronic obstructive pulmonary disease (COPD), and a second cohort of similarly matched patients without HP or COPD. Results 210 pfHP patients (median age=62, male=59%) were identified. Compared to matched controls without COPD, 5 years prior to their HP diagnosis, pfHP patients had an increased risk of asthma (RR 2.9 [1.9-4.4], p<0.001), cardiac disease (RR 2.4 [1.4-4.0], p=0.002), atrial fibrillation (RR 3.1[1.5-6.4], p=0.002) and hypertension (RR 1.3 [1.0-1.7], p=0.04) and gastro-oesophageal reflux disease (RR 1.9 [1.1-3.4], p=0.02). Compared to matched COPD controls, pfHP patients were at higher risk of asthma (RR 1.6 [1.2-2.2], p=0.005) and death (log-rank test, p<0.001). Conclusion The increased documentation of asthma prior to HP diagnosis suggests that individuals predisposed to HP may exhibit asthma-like prodromal symptoms a decade before a formal HP diagnosis. These findings have implications for our understanding of the early pathophysiological evolution of fibrotic HP and its early detection.
- 27 March 2025
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 10, 164
Open AccessPrevalent comorbidity in patients with hypersensitivity pneumonitis: a UK primary care population study
Background Existing data on the prevalence of comorbidities in patients prior to a diagnosis of hypersensitivity pneumonitis (HP) is sparse. Methods Patients with two read codes of HP diagnosed between 01/01/1997 and 01/01/2019, were identified from the Clinical Practice Research Datalink GOLD database multiple registrations cohort. Included patients with a restrictive defect on pulmonary function testing were defined as probable fibrotic HP (pfHP). The incidence of a range of comorbidities was compared to age, gender and smoking matched patients with chronic obstructive pulmonary disease (COPD), and a second cohort of similarly matched patients without HP or COPD. Results 210 pfHP patients (median age=62, male=59%) were identified. Compared to matched controls without COPD, 5 years prior to their HP diagnosis, pfHP patients had an increased risk of asthma (RR 2.9 [1.9-4.4], p<0.001), cardiac disease (RR 2.4 [1.4-4.0], p=0.002), atrial fibrillation (RR 3.1[1.5-6.4], p=0.002) and hypertension (RR 1.3 [1.0-1.7], p=0.04) and gastro-oesophageal reflux disease (RR 1.9 [1.1-3.4], p=0.02). Compared to matched COPD controls, pfHP patients were at higher risk of asthma (RR 1.6 [1.2-2.2], p=0.005) and death (log-rank test, p<0.001). Conclusion The increased documentation of asthma prior to HP diagnosis suggests that individuals predisposed to HP may exhibit asthma-like prodromal symptoms a decade before a formal HP diagnosis. These findings have implications for our understanding of the early pathophysiological evolution of fibrotic HP and its early detection.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2430
Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review
Purpose: To examine the accuracy of CT radiomics to predict histopathological features of aggressiveness in lung cancer using a systematic review. Methods: Data sources searched included Medline, Embase, Web of Science, and Cochrane Library from up to 3 November 2023. Included studies reported test accuracy of CT radiomics models to detect the presence of: spread through air spaces (STAS), predominant adenocarcinoma pattern, adenocarcinoma grade, lymphovascular invasion (LVI), tumour infiltrating lymphocytes (TIL) and tumour necrosis, in patients with lung cancer. Two reviewers independently assessed articles for inclusion and methodological quality using QUADAS-2. Results: Eleven studies were included in the final analysis. 10/11 studies were in East Asian populations. 4/11 studies investigated STAS, 6/11 investigated adenocarcinoma invasiveness or growth pattern, and 1/11 investigated LVI. No studies investigating TIL or tumour necrosis met inclusion criteria. Studies were of mixed to poor methodological quality. Reported accuracies for radiomic models ranged from 0.67 to 0.94. Conclusion: Many studies were excluded due to lack of external validation. Due to the high risk of bias and concerns regarding applicability, the evidence is inconclusive as to whether radiomics can accurately predict histopathological features of cancer aggressiveness.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2430
Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review
Purpose: To examine the accuracy of CT radiomics to predict histopathological features of aggressiveness in lung cancer using a systematic review. Methods: Data sources searched included Medline, Embase, Web of Science, and Cochrane Library from up to 3 November 2023. Included studies reported test accuracy of CT radiomics models to detect the presence of: spread through air spaces (STAS), predominant adenocarcinoma pattern, adenocarcinoma grade, lymphovascular invasion (LVI), tumour infiltrating lymphocytes (TIL) and tumour necrosis, in patients with lung cancer. Two reviewers independently assessed articles for inclusion and methodological quality using QUADAS-2. Results: Eleven studies were included in the final analysis. 10/11 studies were in East Asian populations. 4/11 studies investigated STAS, 6/11 investigated adenocarcinoma invasiveness or growth pattern, and 1/11 investigated LVI. No studies investigating TIL or tumour necrosis met inclusion criteria. Studies were of mixed to poor methodological quality. Reported accuracies for radiomic models ranged from 0.67 to 0.94. Conclusion: Many studies were excluded due to lack of external validation. Due to the high risk of bias and concerns regarding applicability, the evidence is inconclusive as to whether radiomics can accurately predict histopathological features of cancer aggressiveness.
- Open Access
- 17 May 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (9) , 681-689
Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review
- 17 May 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (9) , 681-689
Open AccessPredicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review
- Open Access
- 17 March 2021
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 8 (1) , e000813
Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis
Background Descriptions of clinical characteristics of patients hospitalised withCOVID-19, their clinical course and short-term inpatient and outpatient outcomes in deprived urban populations in the UK are still relatively sparse. We describe the epidemiology, clinical course, experience of non-invasive ventilation and intensive care, mortality and short-term sequelae of patients admitted to two large District General Hospitals across a large East London National Health Service Trust during the first wave of the pandemic. Methods A retrospective analysis was carried out on a cohort of 1946 patients with a clinical or laboratory diagnosis of COVID-19, including descriptive statistics and survival analysis. A more detailed analysis was undertaken of a subset of patients admitted across three respiratory units in the trust. Results Increasing age, male sex and Asian ethnicity were associated with worse outcomes. Increasing severity of chest X-ray abnormalities trended with mortality. Radiological changes persisted in over 50% of cases at early follow-up (6 weeks). Ongoing symptoms including hair loss, memory impairment, breathlessness, cough and fatigue were reported in 70% of survivors, with 39% of patients unable to return to work due to ongoing symptoms. Conclusions Understanding the acute clinical features, course of illness and outcomes of COVID-19 will be crucial in understanding the effect of differences in risk, as well as the effectiveness of new interventions and vaccination between the successive waves of the pandemic.
- 17 March 2021
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 8 (1) , e000813
Open AccessClinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis
Background Descriptions of clinical characteristics of patients hospitalised withCOVID-19, their clinical course and short-term inpatient and outpatient outcomes in deprived urban populations in the UK are still relatively sparse. We describe the epidemiology, clinical course, experience of non-invasive ventilation and intensive care, mortality and short-term sequelae of patients admitted to two large District General Hospitals across a large East London National Health Service Trust during the first wave of the pandemic. Methods A retrospective analysis was carried out on a cohort of 1946 patients with a clinical or laboratory diagnosis of COVID-19, including descriptive statistics and survival analysis. A more detailed analysis was undertaken of a subset of patients admitted across three respiratory units in the trust. Results Increasing age, male sex and Asian ethnicity were associated with worse outcomes. Increasing severity of chest X-ray abnormalities trended with mortality. Radiological changes persisted in over 50% of cases at early follow-up (6 weeks). Ongoing symptoms including hair loss, memory impairment, breathlessness, cough and fatigue were reported in 70% of survivors, with 39% of patients unable to return to work due to ongoing symptoms. Conclusions Understanding the acute clinical features, course of illness and outcomes of COVID-19 will be crucial in understanding the effect of differences in risk, as well as the effectiveness of new interventions and vaccination between the successive waves of the pandemic.